US 12,263,234 B2
Anti-PD-L1 diabodies and the use thereof
Lieping Chen, Beijing (CN); Zhenguo Wen, Beijing (CN); Liqun Luo, Beijing (CN); and Qianyong Liu, Beijing (CN)
Assigned to Tayu Huaxia Biotech Medical Group Co., Ltd., Beijing (CN)
Appl. No. 17/425,296
Filed by Tayu Huaxia Biotech Medical Group Co., Ltd., Beijing (CN)
PCT Filed Jan. 17, 2020, PCT No. PCT/CN2020/072572
§ 371(c)(1), (2) Date Jul. 22, 2021,
PCT Pub. No. WO2020/151572, PCT Pub. Date Jul. 30, 2020.
Prior Publication US 2022/0088232 A1, Mar. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 51/10 (2006.01); A61K 39/00 (2006.01); C07K 16/28 (2006.01)
CPC A61K 51/1093 (2013.01) [C07K 16/2827 (2013.01); A61K 2039/505 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2317/626 (2013.01); C07K 2317/92 (2013.01)] 24 Claims
 
1. An isolated anti-PD-L1 diabody comprising a first polypeptide and a second polypeptide, wherein the first polypeptide comprises a first heavy chain variable region (VH-1) and a first light chain variable region (VL-1), and wherein the second polypeptide comprises a second heavy chain variable region (VH-2) and a second light chain variable region (VL-2), and wherein:
a) the VH-1 and the VH-2 each comprises an HC-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an HC-CDR2 comprising the amino acid sequence of SEQ ID NO: 6, and an HC-CDR3 comprising the amino acid sequence of SEQ ID NO: 11; and
b) the VL-1 and the VL-2 each comprises an LC-CDR1 comprising the amino acid sequence of SEQ ID NO: 14, an LC-CDR2 comprising the amino acid sequence of SEQ ID NO: 17, and an LC-CDR3 comprising the amino acid sequence of SEQ ID NO: 20.